Choice of a nonsteroidal anti-inflammatory drug in ankylosing spondylitis

Abstract

Анкилозирующий спондилит (АС) -хроническое системное заболевание с преимущественным поражением аксиального скелета Ankylosing spondylitis (AS) is a chronic systemic disease with predominant axial skeleton injury, peripheral articular and entheseal involvements, and extra-skeletal manifestations. 8-10 years elapse since the first manifestations of AC to its diagnosis, leading to delays in adequate therapy, to the progression of structural and functional impairments in the axial skeleton and peripheral joints and to the development of complications. According to the international and Russia's Association of Rheumatologists guidelines, nonsteroidal anti-inflammatory drugs (NSAIDs) are an important component of AS therapy. It is necessary to carefully choose the safest NSAID for these patients, by taking into consideration that AS therapy should be long-term and continuous. The trial previously performed by the authors evaluated comorbidity in 220 AS